Cochlear Ltd (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$15.45 billion
P/E Ratio
58.82
Dividend Yield
1.28%
Shares Outstanding
65.66 million
Earnings per share
3.975
Dividend per share
3.10
Year To Date Return
15.29%
Earnings Yield
1.70%
Franking
35
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Ltd (ASX: COH)
Latest News
Blue Chip Shares
Analysts say these 4 ASX blue chip shares are buys
Share Market News
Returning capital: These ASX companies have been buying back their shares in 2023
Broker Notes
Analysts say these ASX 100 shares are buys right now
Blue Chip Shares
Analysts say these ASX 200 stocks are quality buys for FY24
Broker Notes
These high quality ASX 200 shares could be buys in July
Healthcare Shares
Cochlear share price lower on acquisition update
Share Market News
5 things to watch on the ASX 200 on Friday
Broker Notes
‘Dual tailwinds’: 2 quality ASX 200 shares to buy for long-term wealth
Growth Shares
ASX growth shares could be primed for a rally. Is it time to jump back in?
Dividend Investing
4 things to look for when buying ASX dividend stocks
Broker Notes
Brokers say these high-quality ASX 50 shares are buys
Blue Chip Shares
Strengthen your portfolio with these ASX 200 blue chip shares
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year. From October 2019, dividends were unfranked until October 2022 when dividends were 40% franked.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 21 Mar 2023 | $1.5500 | 35.00% | Interim | 14 Apr 2023 |
| 21 Sep 2022 | $1.4500 | 40.00% | Final | 17 Oct 2022 |
| 28 Mar 2022 | $1.5500 | 0.00% | Interim | 21 Apr 2022 |
| 23 Sep 2021 | $1.4000 | 0.00% | Final | 18 Oct 2021 |
| 25 Mar 2021 | $1.1500 | 0.00% | Interim | 20 Apr 2021 |
| 19 Sep 2019 | $1.7500 | 100.00% | Final | 14 Oct 2019 |
| 25 Mar 2019 | $1.5500 | 100.00% | Interim | 16 Apr 2019 |
| 17 Sep 2018 | $1.6000 | 100.00% | Final | 10 Oct 2018 |
| 19 Mar 2018 | $1.4000 | 100.00% | Interim | 12 Apr 2018 |
| 19 Sep 2017 | $1.0000 | 100.00% | Final | 11 Oct 2017 |
| 15 Mar 2017 | $1.3000 | 100.00% | Interim | 06 Apr 2017 |
| 07 Sep 2016 | $1.2000 | 100.00% | Final | 29 Sep 2016 |
| 10 Mar 2016 | $1.1000 | 100.00% | Interim | 01 Apr 2016 |
| 02 Sep 2014 | $1.2700 | 20.00% | Final | 25 Sep 2014 |
| 20 Feb 2006 | $0.4500 | 100.00% | Interim | 14 Mar 2006 |
| 26 Aug 2005 | $0.4500 | 100.00% | Final | 22 Sep 2005 |
| 19 Feb 2004 | $0.3500 | 100.00% | Interim | 17 Mar 2004 |
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Ltd
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
COH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 09 Aug 2023 | $233.31 | $-0.48 | -0.21% | 98,769 | $232.50 | $234.00 | $231.52 |
| 08 Aug 2023 | $233.79 | $0.47 | 0.20% | 104,709 | $233.70 | $234.63 | $232.78 |
| 07 Aug 2023 | $233.32 | $-2.06 | -0.88% | 62,827 | $234.89 | $236.34 | $233.15 |
| 04 Aug 2023 | $235.38 | $-0.33 | -0.14% | 97,858 | $233.18 | $235.67 | $232.19 |
| 03 Aug 2023 | $235.71 | $-1.45 | -0.61% | 113,391 | $235.54 | $237.25 | $234.32 |
| 02 Aug 2023 | $237.16 | $-1.71 | -0.72% | 89,366 | $238.79 | $240.83 | $237.06 |
| 01 Aug 2023 | $238.87 | $-0.31 | -0.13% | 81,817 | $237.26 | $240.12 | $235.78 |
| 31 Jul 2023 | $239.18 | $0.11 | 0.05% | 91,537 | $239.10 | $240.95 | $236.72 |
| 28 Jul 2023 | $239.07 | $-1.92 | -0.80% | 93,308 | $238.99 | $240.65 | $236.69 |
| 27 Jul 2023 | $240.99 | $4.19 | 1.77% | 108,079 | $236.63 | $241.56 | $236.00 |
| 26 Jul 2023 | $236.80 | $1.23 | 0.52% | 91,704 | $236.81 | $237.73 | $234.84 |
| 25 Jul 2023 | $235.57 | $0.79 | 0.34% | 84,594 | $234.50 | $236.25 | $233.36 |
| 24 Jul 2023 | $234.78 | $0.91 | 0.39% | 101,296 | $234.99 | $235.69 | $233.84 |
| 21 Jul 2023 | $233.87 | $0.42 | 0.18% | 83,007 | $232.46 | $234.89 | $232.46 |
| 20 Jul 2023 | $233.45 | $-1.68 | -0.71% | 87,523 | $234.21 | $236.12 | $232.97 |
| 19 Jul 2023 | $235.13 | $2.86 | 1.23% | 159,706 | $233.05 | $235.22 | $232.22 |
| 18 Jul 2023 | $232.27 | $-0.25 | -0.11% | 104,210 | $231.01 | $233.02 | $228.00 |
| 17 Jul 2023 | $232.52 | $2.17 | 0.94% | 113,441 | $231.56 | $233.62 | $230.28 |
| 14 Jul 2023 | $230.35 | $2.27 | 1.00% | 135,572 | $228.20 | $231.60 | $227.67 |
| 13 Jul 2023 | $228.08 | $4.93 | 2.21% | 167,276 | $226.07 | $228.58 | $226.04 |
| 12 Jul 2023 | $223.15 | $-2.34 | -1.04% | 100,838 | $224.71 | $225.59 | $222.47 |
| 11 Jul 2023 | $225.49 | $3.59 | 1.62% | 80,507 | $223.78 | $225.49 | $222.74 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 06 Mar 2023 | Michael del Prado | Buy | 132 | $19,877 |
On-market trade. US $
|
| 01 Nov 2022 | Michael del Prado | Buy | 150 | $19,200 |
On-market trade. USD$
|
| 26 Oct 2022 | Catriona Deans | Buy | 500 | $97,485 |
On-market trade.
|
| 24 Oct 2022 | Karen Penrose | Buy | 128 | $24,960 |
On-market trade.
|
| 24 Oct 2022 | Bruce Robinson | Buy | 102 | $19,876 |
On-market trade.
|
| 19 Oct 2022 | Dig Howitt | Issued | 19 | $3,842,976 |
Issue of securities.
|
| 19 Oct 2022 | Dig Howitt | Issued | 6 | $1,216,294 |
Issue of securities. 27,704 RIGHTS
|
| 29 Sep 2022 | Dig Howitt | Issued | 3 | $678,628 |
Issue of securities. 21,663 rights
|
| 09 Sep 2022 | Karen Penrose | Buy | 190 | $39,900 |
On-market trade.
|
| 01 Sep 2022 | Michael del Prado | Buy | 200 | $29,500 |
As advised by the company. Purchase of 200 Shares on the United
States over-the-counter (OTC) market US $ |
| 30 Aug 2022 | Michael del Prado | Buy | 100 | $14,900 |
As advised by the company. Purchase of 100 Shares on the United
States over-the-counter (OTC) market US $ |
| 26 Aug 2022 | Karen Penrose | Buy | 232 | $49,634 |
On-market trade.
|
| 25 Aug 2022 | Christine McLoughlin | Buy | 250 | $54,785 |
On-market trade.
|
| 24 Aug 2022 | Michael Daniell | Buy | 200 | $43,036 |
On-market trade.
|
| 24 Aug 2022 | Karen Penrose | Buy | 228 | $49,991 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Christine Frances McLoughlin | Non-Executive Director | Nov 2020 |
Ms McLoughlin has served on the boards of a number of ASX50 companies and is a company director with domestic and international experience. She has experience covering health, insurance, resources, infrastructure and financial services.
|
| Mr Michael Grenfell Daniell | Non-Executive Director | Jan 2020 |
Mr Daniell has over 40 years' experience in the medical device industry with executive leadership experience. Former Managing Director and CEO of Fisher & Paykel Healthcare Corporation Limited responsible for the global business and operations including the design, manufacture and marketing of innovative products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea.
|
| Ms Catriona Alison Deans | Non-Executive DirectorNon-Executive Chairman | Jan 2015 |
Ms Deans has experience in technology-enabled businesses across e-commerce, media and financial services. She is former Chief Executive Officer of netus, Hoyts Cinemas, ecorp and eBay Australia and New Zealand.
|
| Mr Andrew Leslie Denver | Non-Executive Director | Feb 2007 |
Mr Denver has experience in the life sciences industry. He is former Managing Director of Memtec Limited and President Asia for Pall Corporation.
|
| Ms Yasmin Anita Allen | Non-Executive Director | Aug 2010 |
Ms Allen has career in investment banking with senior roles in strategic analysis and corporate advice. Former Vice President of Deutsche Bank AG, Director of ANZ Investment Bank and Associate Director of HSBC London.
|
| Ms Karen Lee Collett Penrose | Non-Executive Director | Jul 2022 |
Ms Penrose has career in senior leadership and Chief Financial Officer roles in financial services. She served on the boards of a number of ASX100 companies and experienced across health care, financial services, property and infrastructure industries.
|
| Mr Glen Francis Boreham | Non-Executive Director | Jan 2015 |
Mr Boreham led organisations in information technology, new media and the creative industries through periods of rapid change and innovation. Former Managing Director of IBM Australia and New Zealand. He is Director of Southern Cross Media Group and Link Group and Strategic Advisor of IXUP.
|
| Professor Bruce Gregory Robinson | Non-Executive Director | Dec 2016 |
Prof Robinson have 20 years leadership experience as an academic physician/scientist across research, healthcare and medicine, and tertiary education. Former Dean of The University of Sydney's Sydney Medical School, Head of Medicine at Sydney's Royal North Shore Hospital and Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research. Other boards includes Chairman, National Health and Medical Research Council. Director, MaynePharma, QBiotocs and Ecofibre. Director, Woolcock Institute of Medical Research and Senior Advisor to McKinsey & Company and MinterEllison.
|
| Mr Dig Howitt | PresidentChief Executive OfficerManaging Director | Jul 2017 |
Mr Howitt has experience across the Company in roles including Chief Operating Officer, President, Asia Pacific and SVP, Manufacturing and Logistics. Dig worked for Boston Consulting Group and held a General Management role at Boral.
|
| Mr Michael del Prado | Non-Executive Director | Jan 2022 |
Mr Prado has over 34 years' global experience in the medical device and pharmaceutical industries with senior executive leadership roles in Johnson & Johnson medical device businesses in the US, Asia-Pac and EMEA.
|
| Mr Ray Jarman | Company Secretary | Feb 2017 |
-
|
| Stu Sayers | Chief Financial Officer |
-
|
|
| David Hackshall | Chief Information Officer |
-
|
|
| Jan Janssen | Chief Technology Officer |
-
|
|
| Ray Jarman | Company Secretary |
-
|
|
| Anthony Bishop | President Asia Pacific & Latin America |
-
|
|
| Richard Brook | President EMEA |
-
|
|
| Lisa Aubert | President North America |
-
|
|
| Brian Kaplan | Senior Vice President Global Clinical Strategy and Innovation |
-
|
|
| Jennifer Hornery | Senior Vice President Global People & Culture |
-
|
|
| Dean Phizacklea | Senior Vice President Global Strategic Marketing |
-
|
|
| Greg Bodkin | Senior Vice President Global Supply Chain |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited (i) | 29,929,736 | 45.50% |
| J P Morgan Nominees Australia Pty Limited | 9,232,006 | 14.04% |
| Citicorp Nominees Pty Limited | 5,195,387 | 7.90% |
| BNP Paribas Noms Pty Ltd <DRP> | 2,049,928 | 3.12% |
| National Nominees Limited | 1,812,476 | 2.76% |
| BNP Paribas Nominees Pty Ltd <Agency Lending DRP A/C> | 715,344 | 1.09% |
| HSBC Custody Nominees (Australia) Limited GSCO ECA | 386,396 | 0.59% |
| HSBC Custody Nominees (Australia) Limited <NT Comnwlth Super CORP A/C> | 360,746 | 0.55% |
| Australian Foundation Investment Company Limited | 324,174 | 0.49% |
| Netwealth Investments Limited <Wrap Services A/C> | 304,947 | 0.46% |
| BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <DRP A/C> | 239,876 | 0.36% |
| Mr Christopher Graham Roberts | 172,387 | 0.26% |
| Citicorp Nominees Pty Limited <Colonial First State INV A/C> | 171,493 | 0.26% |
| Custodial Services Limited <Beneficiaries Holding A/C> | 147,414 | 0.22% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 102,317 | 0.16% |
| BNP Paribas Nominees Pty Ltd ACF Clearstream | 86,107 | 0.13% |
| HSBC Custody Nominees (Australia) Limited (ii) | 63,693 | 0.10% |
| Netwealth Investments Limited <Super Services A/C> | 62,655 | 0.10% |
| Cochlear Incentive Plan Pty Ltd <Cochlear Employee Share A/C> | 60,109 | 0.09% |
| BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient DRP> | 59,445 | 0.09% |